FDA
-
-
-
-
-
-
-
Synlogic (SYBX) Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism
-
-
-
-
-
-
-
Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria
-
-
-
-
-
-
-
Synlogic (SYBX) Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria
-
-
-
-
-
-
-
Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update
-
-
-
-
-
-
-
Synlogic Announces Data Presentations at the 2022 Genetic Metabolic Dieticians International (GMDI) Conference and Garrod Symposium
-
-
-
-
-
-
-
Synlogic and Ginkgo Bioworks Announce Investigational Synthetic Biotic Medicine for the Treatment of Homocystinuria
-
-
-
-
-
-
-
Synlogic (SYBX) Receives Fast-Track Designation for SYNB1618
-
251,531 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All